News | Heart Failure | September 19, 2022

First-in-Human Study Finds Mechanical Circulatory Support and Renal Perfusion Success with the ModulHeart Device

FIH study demonstrated feasibility and safety of cardiorenal support among patients undergoing high-risk PCI 

FIH study demonstrated feasibility and safety of cardiorenal support among patients undergoing high-risk PCI

September 19, 2022 —  A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has demonstrated significant improvement in cardiac output, left ventricular end diastolic pressure, and urine output in patients with heart failure or undergoing high-risk percutaneous coronary intervention (PCI). The findings were presented today during the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium and simultaneously published in JSCAI, the official journal of the Society for Cardiovascular Angiography & Interventions (SCAI). 

There are limited percutaneous hemodynamic support options for patients with heart failure or undergoing high-risk PCI. Current approved devices have limitations that lead to an increase in mortality, morbidity, and higher costs. The ModulHeart device is a novel modular pump implanted percutaneously, providing hemodynamic support through three endovascular pumps which are inserted in series and assembled in parallel into a dedicated self-expandable anchor in the descending aorta.   

In June 2022, four patients were enrolled in the FIH study and underwent high-risk PCI with ModulHeart implanted via transfemoral approach. Mean delivery time was 8 minutes, support time was 49 minutes, and pump removal time was 7 minutes. Under ModulHeart support, cardiac index increased by 25%, central venous pressure decreased by 37%, and left ventricular end diastolic pressure decreased by 78%. Urine output increased by ~9-fold after 15 minutes of support. There was no device malfunction, procedural or device-related adverse events and all patients were alive at 30 days post procedure.

“The first-in-human experience using the ModulHeart device was extremely positive, showing great cardiorenal support and pump function,” said Dr. Philippe Généreux, interventional cardiologist at the Gagnon Cardiovascular Institute at Morristown Medical Center in New Jersey, and senior author of the study. “The device was easy to deliver and assemble. Once in place, it provided substantial hemodynamic benefits. I am looking forward to the upcoming studies to reduce congestion in patients with acute decompensated heart failure.” 

The current study was performed among patients undergoing high-risk PCI with some degree of left ventricular dysfunction. The researchers state that future studies will target patients with acute and chronic decompensated heart failure with more profound reduced ejection fraction and requiring hemodynamic support and will also explore longer use of the device during the procedure. 

For more information: www.scai.org 


Find more TCT22 coverage here  


Related Content

News | SCAI

May 7, 2024 — Medtronic announced the release of important clinical outcomes in two leading transcatheter valve ...

Home May 07, 2024
Home
News | SCAI

May 7, 2024 — Women and black patients were less frequently treated with minimally invasive therapy compared to men or ...

Home May 07, 2024
Home
News | SCAI

May 1, 2024 — The annual Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific ...

Home May 01, 2024
Home
News | SCAI

June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor ...

Home June 01, 2023
Home
News | SCAI

May 24, 2023 — The largest interventional study focused on pulmonary embolisms highlighted importance of rapid removal ...

Home May 24, 2023
Home
Feature | SCAI | Christine Book

May 23, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) welcomed its 46th President and 2023 ...

Home May 23, 2023
Home
News | SCAI

May 19, 2023 — Findings from a study examining the relationship between marijuana use and peripheral artery disease (PAD ...

Home May 19, 2023
Home
News | SCAI

February 7, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) announced the second application ...

Home February 07, 2023
Home
News | SCAI

January 18, 2023 — the Society for Cardiovascular Angiography & Interventions (SCAI) announced four recipients of their ...

Home January 18, 2023
Home
News | SCAI

December 8, 2022 — The Society for Cardiovascular Angiography & Interventions (SCAI), a leading nonprofit medical ...

Home December 08, 2022
Home
Subscribe Now